These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 19133206)

  • 21. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
    Chen JT; Pucino F; Resman-Targoff BH
    J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
    Tegeder I; Geisslinger G
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Apr; 373(1):1-17. PubMed ID: 16586083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Elliott WJ
    Curr Hypertens Rep; 2010 Aug; 12(4):258-66. PubMed ID: 20524091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM
    Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 inhibitors and cardiovascular risk.
    Salzberg DJ; Weir MR
    Subcell Biochem; 2007; 42():159-74. PubMed ID: 17612050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.
    Aldington S; Shirtcliffe P; Weatherall M; Beasley R
    N Z Med J; 2005 Nov; 118(1226):U1755. PubMed ID: 16311613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiovascular risk of cyclooxygenase selective inhibitors].
    Terán-Estrada L; Miranda-Limón JM; Galván-Villegas F
    Rev Med Inst Mex Seguro Soc; 2008; 46(3):287-99. PubMed ID: 19133206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COX-2 selective inhibitors and heart health.
    Simon LS; White WB
    Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Krum H; Liew D; Aw J; Haas S
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.